A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT05592626

Public ClinicalTrials.gov record NCT05592626. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 4, 2026, 4:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with advanced solid tumors that are antigen-rich.

Study identification

NCT ID: NCT05592626
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Marengo Therapeutics, Inc.; Industry
Enrollment: 366 participants

Conditions and interventions

Conditions

Interventions

STAR0602 Drug
Irinotecan (Camptosar) Combination Product
Docetaxel (Taxotere) Combination Product

Drug · Combination Product

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 3, 2023
Primary completion: Aug 31, 2027
Completion: Aug 31, 2027
Last update posted: Aug 10, 2026

2023 – 2027

United States locations

U.S. sites: 13
U.S. states: 11
U.S. cities: 13

Facility	City	State	ZIP	Site status
UC Davis Comprehensive Cancer Center	Sacramento	California	95817	Active, not recruiting
AdventHealth Celebration	Celebration	Florida	34747	Recruiting
University of Miami Sylvester Comprehensive Cancer Center	Miami	Florida	33136	Active, not recruiting
The University of Kansas Cancer Center	Kansas City	Kansas	66160	Recruiting
National Institutes of Health	Bethesda	Maryland	20892	Recruiting
Massachusetts General Hospital Cancer Center	Boston	Massachusetts	02114	Recruiting
Karmanos Cancer Institute	Detroit	Michigan	48201	Recruiting
The Ohio State University Comprehensive Cancer Center	Columbus	Ohio	43210	Recruiting
Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville)	Nashville	Tennessee	37203	Recruiting
The University of Texas, MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
UT Health Mays Cancer Center	San Antonio	Texas	78229	Recruiting
Fred Hutchinson Cancer Center	Seattle	Washington	98109	Active, not recruiting
University of Wisconsin- Madison	Madison	Wisconsin	53792	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05592626, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 10, 2026 · Synced Sep 4, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05592626 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →